BioSpace News Archive

The planned Phase 1 trial studying Actimab-A in combination with CLAG-M will be an investigator initiated trial conducted at the Medical College of Wisconsin in a Phase 1, dose escalation study.

The Company expects to report the financial results for the fourth quarter and full year of 2017 after 5:00 PM ET on Tuesday, February 27, 2018.

To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.

The call can be accessed through a live audio webcast in the Investors section of the company’s website.

Results from randomized phase II CONDOR trial suggest the immune checkpoint blocker is safe and shows encouraging anti-tumor activity as second-line treatment in tumors with low/negative PD-L1; no difference in clinical activity observed between durvalumab alone or in combination with tremelimumab [13-February-2018] SCOTTSDALE, Ariz., Feb. 13, 2018 /PRNewswir

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the HPV, including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially.

Strong momentum from 2017 fuels strong start for Athenex in 2018.

The Kendall Square facility will support robust customer growth and connect Alcami to the forefront of hundreds of thriving pharma and biotech start-ups and innovators.

This information will be available on the Company’s website www.kewaunee.com after the release.

Bionik today announced its third quarter fiscal year 2018 financial results for the three and nine months ended December 31, 2017.